Safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-1301, an oral PCSK9 inhibitor, in healthy participants: a first-in-human, randomized, double-blind, placebo-controlled phase I trial
Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) is a proven therapeutic strategy for reducing plasma low density lipoprotein-cholesterol (LDL-C). HRS-1301 is an oral small molecule PCSK9 inhibitor designed to prevent LDL receptor degradation, representing a novel therapeutic approach for dysli...